ASLAN Pharmaceuticals Completes Enrolment in Second Cohort and Opens New Sites in US and Australia in ASLAN004 Atopic Dermati...
21 September 2020 - 12:00PM
ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology
and oncology focused biopharmaceutical company developing
innovative treatments to transform the lives of patients, today
announced that clinical sites in the US and Australia are now open
and ready to enrol patients into its multiple ascending dose (MAD)
study testing the first-in-class therapeutic antibody ASLAN004 in
moderate to severe atopic dermatitis (AD) patients. Patients will
now be recruited from 4 sites in Australia, 3 sites in the US
alongside 2 existing sites in Singapore.
ASLAN recently restarted recruitment into the second cohort of
the randomised, double blind, placebo-controlled study in Singapore
following the lifting of government restrictions in response to
COVID-19. All 8 patients have now been fully recruited into the
cohort and ASLAN plans to initiate recruitment into the third
cohort following approval by the Data Monitoring Committee. A
further 8 patients will be recruited in Singapore, the US and
Australia. ASLAN expects to report interim, unblinded data from all
3 dose cohorts in 4Q 2020.
Dr Kenneth Kobayashi,
Chief Medical Officer, ASLAN
Pharmaceuticals, said: “The speed at which we have been
able to fully recruit the second cohort of the MAD study since
restrictions lifted in Singapore last month reaffirms the scale of
the demand by patients and the interest of physicians for
innovative treatments for AD. We accelerated our plans to open new
study sites in the US and Australia, and are pleased that the sites
are now ready to recruit.”
ASLAN004 is a first-in-class monoclonal antibody that binds to
the IL-13 receptor α1 subunit (IL-13Rα1), blocking signalling of
two pro-inflammatory cytokines, IL-4 and IL-13, which are central
to triggering symptoms of AD, such as redness and itching of the
skin.
Ends
Media and IR
contacts
Emma ThompsonSpurwing CommunicationsTel: +65 6751
2021Email: ASLAN@spurwingcomms.com |
Robert UhlWestwicke PartnersTel: +1 858 356 5932
Email: robert.uhl@westwicke.com |
About ASLAN PharmaceuticalsASLAN
Pharmaceuticals (Nasdaq:ASLN) is a clinical-stage immunology and
oncology focused biopharmaceutical company developing innovative
treatments to transform the lives of patients. Led by a senior
management team with extensive experience in global development and
commercialisation, ASLAN has a clinical portfolio comprised of a
first-in-class monoclonal therapy, ASLAN004, that is being
developed in atopic dermatitis and other immunology indications,
and a small molecule inhibitor targeting oncology. ASLAN’s partners
include Almirall, Array BioPharma, Bristol-Myers Squibb, and CSL.
For additional information please visit www.aslanpharma.com.
Forward
looking
statements
This release contains forward-looking statements. These
statements are based on the current beliefs and expectations of the
management of ASLAN Pharmaceuticals Limited and/or its affiliates
(the "Company"). These forward-looking statements may include, but
are not limited to, statements regarding the Company’s business
strategy, the Company’s plans to develop and commercialise
ASLAN004, the safety and efficacy of ASLAN004, and the Company’s
plans and expected timing with respect to enrolment in its clinical
trials for ASLAN004 and clinical study results for ASLAN004. The
Company’s estimates, projections and other forward-looking
statements are based on management's current assumptions and
expectations of future events and trends, which affect or may
affect the Company’s business, strategy, operations or financial
performance, and inherently involve significant known and unknown
risks and uncertainties. Actual results and the timing of events
could differ materially from those anticipated in such
forward-looking statements as a result of these risks and
uncertainties, which include, without limitation the risk factors
described in the Company’s U.S. Securities and Exchange Commission
filings and reports (Commission File No. 001-38475), including the
Company’s Form 20-F filed with the U.S. Securities and Exchange
Commission (the “SEC”) on April 16, 2020.
All statements other than statements of historical fact are
forward-looking statements. The words “believe,” “may,” “might,”
“could,” “will,” “aim,” “estimate,” “continue,” “anticipate,”
“intend,” “expect,” “plan,” or the negative of those terms, and
similar expressions that convey uncertainty of future events or
outcomes are intended to identify estimates, projections and other
forward-looking statements. Estimates, projections and other
forward-looking statements speak only as of the date they were
made, and, except to the extent required by law, the Company
undertakes no obligation to update or review any estimate,
projection or forward-looking statement.
ASLAN Pharmaceuticals (NASDAQ:ASLN)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
ASLAN Pharmaceuticals (NASDAQ:ASLN)
Historical Stock Chart
Von Jul 2023 bis Jul 2024